Acadia Pharmaceuticals says USPTO allows trofinetide dosing patent application, extending U.S. protection to March 2041
ACAD•Acadia Pharmaceuticals received a USPTO Notice of Allowance for a U.S. patent covering weight-banded dosing of trofinetide for Rett syndrome. The expected patent term, including six months of pediatric exclusivity, runs through March 28, 2041, nearly five years longer than current protection.
1. Patent allowance
Acadia Pharmaceuticals said the USPTO issued a Notice of Allowance for a U.S. patent covering weight-banded dosing of trofinetide for Rett syndrome. The expected patent term, including six months of pediatric exclusivity, runs through March 28, 2041, extending protection by nearly five years.
2. Existing protection
Trofinetide also has a U.S. method-of-use patent for Rett syndrome that expires in July 2036. The drug is marketed in the U.S. as DAYBUE and DAYBUE STIX for adults and pediatric patients ages 2 and older.
